BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torres HA, Pundhir P, Mallet V. Hepatitis C Virus Infection in Patients With Cancer: Impact on Clinical Trial Enrollment, Selection of Therapy, and Prognosis.Gastroenterology. 2019;157:909-916. [PMID: 30797794 DOI: 10.1053/j.gastro.2019.01.271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Koullias Y, Hammond SP. The Promise of Direct-Acting Antiviral Therapies to Improve Care and Outcomes in Patients With Cancer Who Have Chronic Hepatitis C Infection. J Oncol Pract 2019;15:639-40. [PMID: 31825757 DOI: 10.1200/JOP.19.00664] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Frigeni M, Besson C, Visco C, Fontaine H, Goldaniga M, Visentini M, Pulsoni A, Torres HA, Peveling-Oberhag J, Rossotti R, Zaja F, Rigacci L, Merli M, Dorival C, Alric C, Piazza F, Gentile M, Ferrari A, Pirisi M, Nassi L, Rattotti S, Frustaci A, Milella M, Cencini E, Defrancesco I, Ferretti VV, Bruno R, Hermine O, Arcaini L. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia. 2020;34:1462-1466. [PMID: 31836855 DOI: 10.1038/s41375-019-0687-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
3 Umemura M, Suda G, Tsukamoto S, Ebata K, Takahash S, Sasaki T, Nakajima S, Hirata K, Ozasa M, Takano M, Katagiri M, Sakamoto N. Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report. BMC Infect Dis 2021;21:389. [PMID: 33906643 DOI: 10.1186/s12879-021-06091-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pritchard H, Jandhyala D, Hosry J, Angelidakis G, Torres HA. Salvage therapy in cancer patients with hepatitis C without sustained virologic response after direct-acting antivirals-A prospective study. JGH Open 2020;4:541-4. [PMID: 32514467 DOI: 10.1002/jgh3.12294] [Reference Citation Analysis]
5 Li YR, Hu TH, Chen WC, Hsu PI, Chen HC. Screening and prevention of hepatitis C virus reactivation during chemotherapy. World J Gastroenterol 2021; 27(31): 5181-5188 [PMID: 34497443 DOI: 10.3748/wjg.v27.i31.5181] [Reference Citation Analysis]
6 Reynolds G, Haeusler G, Slavin MA, Teh B, Thursky K. Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach? Support Care Cancer 2021. [PMID: 33763725 DOI: 10.1007/s00520-021-06116-w] [Reference Citation Analysis]
7 Ziogas DC, Kostantinou F, Cholongitas E, Anastasopoulou A, Diamantopoulos P, Haanen J, Gogas H. Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. J Immunother Cancer 2020;8:e000943. [PMID: 33067316 DOI: 10.1136/jitc-2020-000943] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
8 Angelidakis G, Mahale P, Jonasch E, Jiang Y, Torres HA. Chronic hepatitis C virus infection and genitourinary cancers: A case-control study. Semin Oncol 2020;47:165-7. [PMID: 32507667 DOI: 10.1053/j.seminoncol.2020.04.005] [Reference Citation Analysis]
9 Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review. World J Hepatol 2022; 14(3): 525-534 [DOI: 10.4254/wjh.v14.i3.525] [Reference Citation Analysis]
10 Pritchard H, Hwang JP, Angelidakis G, Yibirin M, Wang L, Miller E, Torres HA. Hepatitis B virus reactivation in cancer patients receiving direct-acting antivirals for hepatitis C virus infection. J Viral Hepat 2021;28:844-8. [PMID: 33523503 DOI: 10.1111/jvh.13478] [Reference Citation Analysis]